Carter T. Fields
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 11
- HER2/EGFR in Cancer Research 11
-
- Monoclonal and Polyclonal Antibodies Research 6
- Co-authors
- Gail D. Lewis Phillips (9 shared papers)Mark X. Sliwkowski (7 shared papers)Kathryn L. Parsons (6 shared papers)Deepak Sampath (3 shared papers)Teemu T. Junttila (3 shared papers)Robert W. Akita (2 shared papers)Lori S. Friedman (1 shared paper)Michael Pickles (2 shared papers)
- Journals
- Cancer Research (5 papers)Gastroenterology (2 papers)Cancer Cell (2 papers)Clinical Cancer Research (1 paper)Trials (1 paper)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Carter T. Fields
17 papers receiving 1.5k citations
Carter T. Fields's Hit Papers
Peers
Comparison fields: 5 of 73
- Oncology 802
- Radiology, Nuclear Medicine and Imaging 445
- Genetics 396
- Immunology 213
- Gastroenterology 45
Countries citing papers authored by Carter T. Fields
This map shows the geographic impact of Carter T. Fields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carter T. Fields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carter T. Fields more than expected).
Fields of papers citing papers by Carter T. Fields
This network shows the impact of papers produced by Carter T. Fields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carter T. Fields. The network helps show where Carter T. Fields may publish in the future.
Co-authors
The 25 scholars most cited alongside Carter T. Fields, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Hit paper breakdown → | 2009 | 688 |
| 2 | 1998 | 325 | |
| 3 | 2013 | 153 | |
| 4 | 2015 | 135 | |
| 5 | 1998 | 122 | |
| 6 | 2006 | 23 | |
| 7 | 2011 | 17 | |
| 8 | 2023 | 14 | |
| 9 | 2010 | 10 | |
| 10 | 2008 | 6 | |
| 11 | 2010 | 5 | |
| 12 | 2010 | 5 | |
| 13 | 2016 | 4 | |
| 14 | Abstract #3239: Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase | 2009 | 3 |
| 15 | 1998 | 3 | |
| 16 | 2012 | 2 | |
| 17 | 2010 | 2 |
About Carter T. Fields
Carter T. Fields is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine, Genetics and Molecular Biology, having authored 17 papers that have together received 1.5k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Inflammatory Bowel Disease (3 papers), Lung Cancer Treatments and Mutations (2 papers), Click Chemistry and Applications (1 paper), Ferroptosis and cancer prognosis (1 paper), Chronic Myeloid Leukemia Treatments (1 paper) and Galectins and Cancer Biology (1 paper). The work is most often cited by research in Oncology (802 citations), Radiology, Nuclear Medicine and Imaging (445 citations), Genetics (396 citations), Immunology (213 citations) and Gastroenterology (45 citations). Carter T. Fields has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Gail D. Lewis Phillips, Mark X. Sliwkowski, Kathryn L. Parsons, Deepak Sampath, Teemu T. Junttila, Robert W. Akita, Lori S. Friedman, Michael Pickles, Theodore M. Bayless and Jasdeep Mann. Their work appears in journals such as Cancer Research, Gastroenterology, Cancer Cell, Clinical Cancer Research and Trials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.